The Safety and Efficacy of Tofacitinib in Pediatric Rheumatic Diseases: Single Centre Experience

    February 2022 in “ Frontiers in Pediatrics ”
    Mikhail M. Kostik, Rinat K. Raupov, Evgeny N. Suspitsin … Vyacheslav Chasnyk
    Studysummary This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study Pediatric Dermatology · 2020
    2. Tofacitinib Therapy for Children with Severe Alopecia Areata Journal of the American Academy of Dermatology · 2019
    3. JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis Rheumatology · 2018
    4. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017